Obstructive sleep apnoea (OSA) is a common sleep disorder characterised by intermittent apnoeas (pauses in breathing) leading to dips in oxygen levels in the blood during sleep. Many people with known or unknown (undiagnosed) OSA receive hypnotics, sedatives and opiate/opioid drugs to treat other conditions including pain, anxiety and difficulty sleeping. Opiates/opioids are commonly prescribed to treat pain after major surgery. These drugs might make sleep apnoea worse - increasing the frequency and duration of apnoeas.
We set out to look at evidence derived from randomised placebo-controlled trials to identify the risks of these drugs for patients with known OSA.
What we did
We searched and reviewed all randomised placebo-controlled trials involving adult patients with known OSA who received these drugs. Most of the trials were short at just one or two nights' duration, involved only a small number of patients and used poorly described methodology. Therefore it was difficult to find out the exact effects of these drugs on patients with OSA.
We found 14 studies examining the effects of 10 drugs in trials including 293 people.
Opiates and opioids (treatment of acute and chronic pain)
Remifentanil infusion did not significantly change severity of OSA as measured by numbers and duration of pauses in breathing during sleep, but it significantly lowered minimum oxygen levels during the night when compared with placebo.
Sedatives and hypnotics
'Z drugs' (a treatment for insomnia, inability to fall asleep or inability to maintain sleep)
Eszopiclone and zolpidem
Eszopiclone did not worsen OSA as measured by the numbers and duration of pauses in breathing during sleep. In one study, it reduced the severity of OSA, and it might be beneficial in treating this condition, although further studies are needed to assess this effect.
Zolpidem did not significantly worsen OSA as measured by the numbers and duration of pauses in breathing during sleep, but in one trial, it significantly lowered minimum oxygen levels during the night when compared with placebo.
Benzodiazepines (short-term relief of severe anxiety, behavioural disturbance or agitation and panic disorders)
Brotizolam, flurazepam, nitrazepam, temazepam and triazolam
None of the drugs examined had significantly worsened OSA as measured by the numbers and duration of pauses in breathing during sleep. In small, single-night studies, zolpidem 20 mg, flurazepam 20 mg and triazolam 0.25 mg showed a tendency to increase numbers and duration of pauses during sleep, which was not statistically significant, but these drugs significantly lowered minimum oxygen levels during the night when compared with placebo.
Sodium oxybate (a treatment for narcolepsy, a condition causing excessive sleepiness during the day)
Sodium oxybate was compared with placebo in two trials. Results showed that sodium oxybate did not worsen OSA as measured by the numbers and duration of pauses in breathing during sleep. In one study, sodium oxybate 4.5 g reduced the severity of OSA and might have proved beneficial in treating this condition, although further studies are needed to assess this effect.
Melatonin and melatonin-related drugs
Ramelteon (a treatment drug for insomnia)
Ramelteon was assessed in older adults, over 60 years of age, with OSA and insomnia and was found not to worsen OSA.
Results of this review show that the drugs studied do not worsen the severity of OSA as measured by the numbers and duration of pauses in breathing during sleep, but significant clinical and statistical decreases in minimum oxygen levels during the night were observed with remifentanil, zolpidem and triazolam; therefore prescribing these drugs for patients with OSA still warrants caution. Sodium oxybate 4.5 g and eszopiclone reduced the severity of OSA and might be beneficial in treating this condition; nonetheless further studies are needed to support these results.
The long-term effect and potential side effects of sedative drugs in people with OSA need to be assessed in larger, longer and methodologically robust studies.
The findings of this review show that currently no evidence suggests that the pharmacological compounds assessed have a deleterious effect on the severity of OSA as measured by change in AHI or ODI. Significant clinical and statistical decreases in minimum overnight SpO2 were observed with remifentanil, zolpidem 20 mg and triazolam 0.25 mg. Eszopiclone 3 mg and sodium oxybate 4.5 g showed a beneficial effect on the severity of OSA with a reduction in AHI and may merit further assessment as a potential therapeutic option for a subgroup of patients with OSA. Only one trial assessed the effect of an opioid (remifentanil); some studies included CPAP treatment, whilst in a significant number of participants, previous treatment with CPAP was not stated and thus a residual treatment effect of CPAP could not be excluded. Most studies were small and of short duration, with indiscernible methodological quality.Caution is therefore required when such agents are prescribed for patients with OSA, especially outside the severity of the OSA cohorts and the corresponding dose of compounds given in the particular studies. Larger, longer trials involving patients across a broader spectrum of OSA severity are needed to clarify these results.
Read the full abstract...
Obstructive sleep apnoea (OSA) is a common sleep disorder characterised by partial or complete upper airway occlusion during sleep, leading to intermittent cessation (apnoea) or reduction (hypopnoea) of airflow and dips in arterial oxygen saturation during sleep. Many patients with recognised and unrecognised OSA receive hypnotics, sedatives and opiates/opioids to treat conditions including pain, anxiety and difficulty sleeping. Concerns have been expressed that administration of these drugs to people with co-existing OSA may worsen OSA.
To investigate whether administration of sedative and hypnotic drugs exacerbates the severity of OSA (as measured by the apnoea-hypopnoea index (AHI) or the 4% oxygen desaturation index (ODI)) in people with known OSA.
We searched the Cochrane Airways Group Specialised Register (CAGR) of trials. The search was current as of March 2015.
Randomised, placebo-controlled trials including adult participants with confirmed OSA, where participants were randomly assigned to use opiates or opioids, sedatives, hypnotics or placebo. We included participants already using continuous positive airway pressure (CPAP) or a mandibular advancement device.
Data collection and analysis:
We used standard methodological procedures as recommended by The Cochrane Collaboration.
Fourteen studies examining the effects of 10 drugs and including a total of 293 participants contributed to this review. Trials were small, with only two trials, which used sodium oxybate, recruiting more than 40 participants, and all but three trials were of only one to three nights in duration. Most participants had mild to moderate OSA with a mean AHI of 11 to 25 events/h, and only two trials recruited patients with severe OSA. Two trials investigating the effects of ramelteon, a treatment option for insomnia, recruited adults over 60 years of age with OSA and concomitant insomnia.
The drugs studied in this review included remifentanil (infusion) 0.75 mcg/kg/h, eszopiclone 3 mg, zolpidem 10 and 20 mg, brotizolam 0.25 mg, flurazepam 30 mg, nitrazepam 10 mg to 15 mg, temazepam 10 mg, triazolam 0.25 mg, ramelteon 8 mg and 16 mg and sodium oxybate 4.5 g and 9 g. We were unable to pool most of the data, with the exception of data for eszopiclone and ramelteon.
None of the drugs in this review produced a significant increase in AHI or ODI. Two trials have shown a beneficial effect on OSA. One study showed that a single administration of eszopiclone 3 mg significantly decreased AHI compared with placebo (24 ± 4 vs 31 ± 5; P value < 0.05), and a second study of sodium oxybate 4.5 g showed a significant decrease in AHI compared with placebo (mean difference (MD) -7.41, 95% confidence interval (CI) -14.17 to -0.65; N = 48).
Only four trials reported outcome data on ODI. No significant increase, in comparison with placebo, was shown with eszopiclone (21 (22 to 37) vs 28.0 (15 to 36); P value = NS), zolpidem (0.81 ± 0.29 vs 1.46 ± 0.53; P value = NS), flurazepam (18.6 ± 19 vs 19.6 ± 15.9; P value = NS) and temazepam (6.53 ± 9.4 vs 6.56 ± 8.3; P value = 0.98).
A significant decrease in minimum nocturnal peripheral capillary oxygen saturation (SpO2) was observed with zolpidem 20 mg (76.8 vs 85.2; P value = 0.002), flurazepam 30 mg (81.7 vs 85.2; P value = 0.002), remifentanil infusion (MD -7.00, 95% CI -11.95 to -2.05) and triazolam 0.25 mg in both rapid eye movement (REM) and non-REM (NREM) sleep (MD -14.00, 95% CI -21.84 to -6.16; MD -10.20, 95% CI -16.08 to -4.32, respectively.
One study investigated the effect of an opiate (remifentanil) on patients with moderate OSA. Remifentanil infusion did not significantly change AHI (MD 10.00, 95% CI -9.83 to 29.83); however it did significantly decrease the number of obstructive apnoeas (MD -9.00, 95% CI -17.40 to -0.60) and significantly increased the number of central apnoeas (MD 16.00, 95% CI -2.21 to 34.21). Similarly, although without significant effect on obstructive apnoeas, central apnoeas were increased in the sodium oxybate 9 g treatment group (MD 7.3 (18); P value = 0.005) in a cross-over trial.
Drugs studied in this review were generally well tolerated, apart from adverse events reported in 19 study participants prescribed remifentanil (n = 1), eszopiclone (n = 6), sodium oxybate (n = 9) or ramelteon (n = 3).
Can opioids make sleep apnea worse? ›
Animal and human studies indicate that opioid use may lead to sleep-disordered breathing. Opioids affect control of breathing and impair upper airway function, causing central apneas, upper airway obstruction, and hypoxemia during sleep.Do sedatives make sleep apnea worse? ›
The muscles in the tongue and soft palate already lose much of their muscular tone while you're asleep; with the addition of sleeping pills, the relaxation becomes even worse. As a result, your sleep apnea is likely to become even more severe than it already is.What medications should you avoid for obstructive sleep apnea? ›
- Some beta-blockers.
- Sildenafil (an erectile dysfunction drug)
- Drugs that cause you to gain weight.
In addition to their well known respiratory depressant effects and potential for addiction, opiates also disrupt sleep architecture, blocking access to rapid eye movement (REM) sleep and to the deeper restorative stages of non-REM sleep.Are opioids contraindicated in sleep apnea? ›
Opioids such as morphine may worsen obstructive sleep apnoea (OSA). Thus, people with OSA may be at greater risk of harm from morphine. Possible mechanisms include respiratory depression and reductions in drive to the pharyngeal muscles to increase upper airway collapsibility.Can oxycodone make sleep apnea worse? ›
This medicine may cause sleep-related breathing problems (eg, sleep apnea, sleep-related hypoxemia). Your doctor may decrease your dose if you have sleep apnea (stop breathing for short periods during sleep) while using this medicine.What is the newest treatment for sleep apnea? ›
For years, the most common treatment for millions of people with sleep apnea involved wearing a continuous positive airway pressure (CPAP) mask. That is, until the U.S. Food and Drug Administration recently approved a new, maskless treatment option -- the Inspire upper airway stimulation device.Can sleep apnea cause altered mental status? ›
Among primary sleep disorders, OSA causes the most serious morbidity and mortality. There is strong evidence that patients with untreated moderate to severe OSA have increased rates of depression, cognitive impairment, and dementia.What aggravates sleep apnea? ›
Having family members with sleep apnea might increase your risk. Use of alcohol, sedatives or tranquilizers. These substances relax the muscles in your throat, which can worsen obstructive sleep apnea. Smoking.Does opioids affect breathing? ›
Opioids such as morphine or fentanyl are powerful substances used to relieve pain in medical settings. However, taken in too high a dose they can depress breathing – in other words, they can lead to slow, shallow breaths that cannot sustain life.
Can pain make sleep apnea worse? ›
Pain causes sleep disorders such as wakefulness and sleep apnea. There is a relationship between pain and sleep disturbances. 8,9 Over 70% of patients with chronic pain disorders report sleep disruption, and lack of restful sleep increases hyperalgesia.How does opioids stop you from breathing? ›
Opioids induce respiratory depression via activation of μ-opioid receptors at specific sites in the central nervous system including the pre-Bötzinger complex, a respiratory rhythm generating area in the pons.What factors can worsen sleep apnea? ›
- Excess weight. Obesity greatly increases the risk of OSA . ...
- Neck circumference. People with thicker necks might have narrower airways.
- A narrowed airway. ...
- Being male. ...
- Being older. ...
- Family history. ...
- Use of alcohol, sedatives or tranquilizers. ...